drugset / Trial / NCT00625547

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

NCT00625547

Phase 3 Completed 361 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.

Timeline

Start
2003-01
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabergoline Small molecule 2 mg Oral
Subject Levodopa Small molecule 100 mg Oral